Epic Bio to Participate in Fireside Chat at Stifel’s Genetic Medicines Forum
23 May 2024
Epic Bio to Participate in Fireside Chat at Stifel’s Genetic Medicines Forum
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, announced that Amber Salzman, Ph.D., chief executive officer, will participate in a fireside chat at Stifel’s 2nd Annual Genetic Medicines Forum, taking place on Tuesday, May 28, 2024 at 10:10 a.m. ET.
Institutional investors should contact their Stifel representatives for additional information.
About Epic Bio
Epic Bio is a leading epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. Epic plans to initiate a clinical trial of its lead program — EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD) — in 2024; additional programs seek to address alpha-1 antitrypsin deficiency (A1AD)alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications. Visit www.epic-bio.com for more information or follow us on X and LinkedIn.
Investor Contact
Benson Cheng
benson.cheng@epic-bio.com
Media Contact
Lisa Raffensperger
lisa@tenbridgecommunications.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.